Resources

Before the COVID-19 pandemic, important progress had been made in improving maternal, neonatal, and child health (MCH) outcomes around the globe, with under-five deaths and maternal mortality falling to historic lows by 2019. However, the onset of the COVID-19 pandemic and resulting mortality has wreaked havoc on broad health outcomes.Over the last two years, PATH has worked alongside governments, donors, and partners around the globe to respond to COVID-19 while working to mitigate its impact by preserving the delivery of essential health services. In early 2022, we conducted an internal analysis to explore COVID-19 disruptions–with a special focus on the impact to MCH essential services–and the innovations that were deployed to address these disruptions. We found that despite reduced budgets for MCH, overstretched workforces, and a reduced focus on universal health care, governments and their partners developed and used a range of innovations at the primary health care (PHC) level intended to safeguard MCH care.Read PATH's full set of recommendations for USAID maternal and child health programming below.

The primary objective of this review is to summarize and assess the current evidence that could support a change to a single-dose schedule of HPV vaccine. The review also aims to identify gaps that remain in determining whether a single dose could be sufficiently protective to have a major impact against HPV infection and its sequelae, within the context of immunization programs. See also the companion resources:General summary (five pages)Technical synthesis (30 pages), of immunogenicity, efficacy, and effectiveness, forthcoming evidence, and areas for future research.Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.

This report focuses on bed net indicators collected from annual cross-sectional surveys and anthropological activities. Within each evaluation, available indicators on bed net ownership, bed net characteristics, and bed net use are presented. Due to country-specific factors, the timing of data collection, management, and analysis varies. Data collection and analysis are ongoing, and definitive conclusions will not be drawn from these results at this time.The New Nets Project (NNP) was established with the goal of making the latest dual active ingredient (AI) insecticide-treated nets (ITNs) more widely available to malaria programs throughout sub-Saharan Africa. In addition to managing the rapid deployment of new nets to partner countries and negotiating a volume guarantee to reduce prices, NNP partners oversee randomized control trials and pilot studies evaluating their efficacy and effectiveness. The evidence gathered from these studies will be used to ascertain the impact and cost-effectiveness of dual AI nets and support an appropriate ITN policy recommendation from the World Health Organization. The NNP is co-funded by Unitaid and The Global Fund, with complementary funding provided by the Bill & Melinda Gates Foundation and US President’s Malaria Initiative. The project is led by IVCC.

The goal of the antenatal care (ANC)-based malaria surveillance study is to assess the potential for pregnant women attending their first ANC visit to be used as an easy-to-access sentinel population at health facilities to monitor trends in prevalence of malaria infection and the coverage of malaria control interventions in study districts, correlated with similar metrics obtained during annual community-based cross-sectional surveys (CSS). The New Nets Project (NNP) is conducting annual cross-sectional surveys in three study districts each in Burkina Faso and western Mozambique and in four study local government areas in Nigeria, with the primary aim of evaluating the impact of next-generation dual active ingredient insecticide-treated nets (ITNs) compared to standard pyrethroid-only ITNs. Through funding from the Bill & Melinda Gates Foundation and The Global Fund, testing for malaria of all pregnant women at during their first ANC visit is being implemented at select health facilities in NNP study districts for two years (2020–2022).This descriptive report presents a summary of preliminary results generated from the first months of data collection in Burkina Faso, Mozambique, and Nigeria. It begins with an overview of the study sites and timeline, followed by a summary of the study population and data collection and analysis methods. The findings from each country are then presented, including prevalence and ITN and care-seeking indicators. Each country section closes with a discussion on the ANC-based surveillance results and how they seemingly compare to results from the annual household CSSs from the NNP.

This is the first resource in a project to develop a supply chain roadmap of vaccine manufacturing in Africa. The project seeks to quantify the gap between today's capacity and desired future capacity to support the Partnerships for African Vaccine Manufacturing Framework for Action, which sets the goal of manufacturing 60 percent of Africa's routine immunization needs on the continent by 2040.This map identifies existing African vaccine manufacturers and their capabilities, as well as provides an initial analysis and conclusions about the current African vaccine manufacturing landscape. This map can be used by national governments, pharmaceutical industry partners, philanthropic foundations, private sector organizations, and others to inform them of the current state of manufacturing and guide their plans for the future.